Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Inhaled steroids effect on bones].

C Weilenmann1, O Lamy, J M Fellrath

  • 1Division d'immunologie et d'allergie, Centre hospitalier universitaire vaudois, Lausanne. cweilenm@hola.hospvd.ch

Revue Medicale De La Suisse Romande
|April 28, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study.

Scientific reports·2024
Same author

Relationship between dietary characteristics and heel quantitative ultrasound parameters in postmenopausal women from the OsteoLaus cohort.

Scientific reports·2024
Same author

Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2022
Same author

Pancreatitis, hypereosinophilia and bilateral pulmonary infiltrates as presentation of acute Q fever.

New microbes and new infections·2021
Same author

Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2021
Same journal

Accelerated sedimentation and hyperproteinemia.

Revue medicale de la Suisse romande·2010
Same journal

Treatment of a hydrothorax.

Revue medicale de la Suisse romande·2010
Same journal

Edema on pilgrim.

Revue medicale de la Suisse romande·2010
Same journal

Lymphosarcoma of the pancreatic compartment.

Revue medicale de la Suisse romande·2010
Same journal

Relief photography.

Revue medicale de la Suisse romande·2010
Same journal

Suture and nerve graft.

Revue medicale de la Suisse romande·2010
See all related articles

Inhaled corticosteroids (ICS) are effective for asthma. Low-dose ICS (<400 mcg/day children, <1000 mcg/day adults) show minimal bone health risks, but higher doses require monitoring.

Area of Science:

  • Pulmonology
  • Endocrinology
  • Pharmacology

Context:

  • Inhaled corticosteroids (ICS) are primary anti-inflammatory agents for asthma management.
  • ICS offer reduced adverse effects on bone metabolism compared to oral steroids.

Purpose:

  • To evaluate the safety of inhaled corticosteroids (ICS) concerning bone health in asthma patients.
  • To define safe dosage thresholds and monitoring strategies for ICS use.

Summary:

  • Reassuring evidence indicates ICS doses ≤400 mcg/day (children) and ≤1000 mcg/day (adults) are safe for bone density and growth.
  • Exceeding these thresholds for >3 months necessitates osteoporosis prevention and potential bone density measurements.
  • Growth monitoring in children and biochemical bone markers can complement bone density assessments.

Related Experiment Videos

Impact:

  • Establishes safe ICS dosage limits for asthma treatment, minimizing bone metabolism risks.
  • Guides clinical practice on monitoring bone health in patients on long-term or high-dose ICS therapy.
  • Highlights potential for new ICS formulations with improved selectivity and reduced bone effects.